OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) has begun to make some serious noise again, and traders may benefit from taking heed. The company has recently snuck out a series of very critical updates that could start to bake in a buzz under the surface and put a bid back in this former high flyer.

The most important recent announcements relate to several key themes that have driven this stock in the past. Earlier in the year, we saw shares of OBMP move over 300% higher in a matter of weeks on similar threads to the company’s narrative. Recently we have seen updates on a new licensing deal in the works, a new trial for the company’s leading pipeline candidate in the $7B prostate cancer space, and a new patent for that same drug, further concretizing the company’s ability to monetize its past R&D expenditures.

OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is a clinical stage biopharmaceutical company that develops cancer immunotherapy products. The company has proprietary rights to a breast and prostate patent vaccine; and a process for the growth of cancer cells and targeted chemotherapies. Its lead product is ProscaVax that is in the planning stage of a Phase II clinical trial for the treatment of prostate cancer.

It’s important to keep in mind that OBMP could be interesting as an easy fit for a few different names as far as a take-out candidate. Just starting with those in the space who have shown a clear interest in development or acquisition of assets that offer potential for market share in the prostate cancer segment, one can easily point to the likes of Seattle Genetics, Inc. (NASDAQ:SGEN), Inovio Pharmaceuticals (NASDAQ:INO), Nymox Pharmaceutical Corporation (NASDAQ:NYMX).

The company also has a portfolio of targeted therapies. OncBioMune Pharmaceuticals, Inc. is headquartered in Baton Rouge, Louisiana.

A Bevy of Activity

As we discussed above, the company has been aggressively on the move in terms of operational activities and updates to the public. But the stock continues to fly under the radar.

One of the most interesting recent developments is the company’s announcement this week that it has achieved a significant milestone with the first patient in Mexico suffering from Chronic Obstructive Pulmonary Disease (COPD) and Alpha-1 Antitrypsin (AAT) deficiency identified and scheduled to begin treatment with a leading therapy in approximately two weeks.

According to the release, the name of the AAT therapy is being withheld at this time for competitive reasons. “OncBioMune is utilizing Mexico’s “Patient Specific” pathway, the equivalent of “Compassionate Use” in the United States, to facilitate importing the product to begin the patient’s therapy immediately. AAT deficiency is a lifelong condition requiring weekly injections, with the cost of some popular insurance-covered therapies in excess of $100,000 annually.” The company notes that it is working to complete licensing negotiations with the treatment’s manufacturer with the goal of adding the product to the Company’s portfolio for the Mexican market.

Approvals could come fast through Orphan channels due to the rarity of the disease and lack of leading treatments.

The company also recently announced that it has been advised that the Mexico health authority, Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) is officially authorizing commencement of their Proscavax study. According to the release, OncBioMune is working with the host hospital, principal investigators and others involved in the trial to begin enrollment immediately.

“This is what we’ve been waiting for and we greatly look forward to enrolling the first patient in the trial in our bid to fill an unmet medical need in Mexico,” commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. “Unfortunately, the more than 300,000 Mexican men diagnosed with prostate cancer each year have limited therapeutic options and none without a high degree of risk of morbidities. We hope to change that with ProscaVax, which we believe will reproduce the strong safety and efficacy profiles that we saw in the Phase 1 study at the University of California San Diego.”

Finally, the company reported that the Mexican Institute of Industrial Property has issued patent No. 343266, titled “Composition and Method for Treating Cancer,” protecting the intellectual rights of OncBioMune’s ProscaVax throughout Mexico until January 8, 2032.

“This patent is particularly important given the Mexican markets are integral to our business model. We expect to announce the official commencement of our Phase 2/3 trial of ProscaVax for late-stage prostate cancer in Mexico any day now, so the timing of the new patent couldn’t be any better,” commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. “An aging population and widespread adoption of screening for prostate specific antigen have Mexico facing a prostate cancer dilemma with little alternatives free of unpleasant side effects. We are optimistic that ProscaVax can provide a safe and effective solution to the nation’s problem for years to come.”

These recent developments could massively increase the company’s potential growth curve by offering a concrete to both near-term and longer-term sales jumps. The stock may be starting to take note. Perhaps, investors should as well.